We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$250M
AUM Growth
-$42.5M
Cap. Flow
-$38.5M
Cap. Flow %
-15.37%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$38.5M

Sector Composition

Rank Sector Weight
1 Healthcare 39.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$131M 52.31%
8,930,237
– –
REPL icon
2
Replimune Group
REPL
$1.01B
$43.2M 17.28%
2,838,968
– –
IFRX icon
3
InflaRx
IFRX
$271M
$27.7M 11.07%
732,670
-1,032,218
-58% -$38.5M
MRNS
4
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$21.1M 8.43%
1,260,684
– –
SLDB icon
5
Solid Biosciences
SLDB
$900M
$18.3M 7.32%
132,630
– –
APTX
6
DELISTED
Aptinyx Inc. Common Stock
APTX
$9.01M 3.6%
2,225,092
– –

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2019 Portfolio in Review

As of Q1 2019, Bain Capital Life Sciences Investors held 6 positions worth $250M, down 15% from $293M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $38.5M in Q1 2019, reducing 1 holding. Its largest reduction was InflaRx, cutting an estimated $38.5M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 62% a quarter earlier.

  • Bain Capital Life Sciences Investors's biggest Q1 2019 reduction was InflaRx, cutting an estimated $38.5M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $250M portfolio in Q1 2019.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 0 in Q1 2019.
  • Bain Capital Life Sciences Investors's portfolio value fell 15% quarter-over-quarter to $250M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2019, filed 15 May 2019.